Article
Oncology
Ling Qi, Jie Peng, Xianbao Huang, Ting Zhou, Genmei Tan, Fei Li
Summary: The gut microbiota is associated with acute graft-versus-host disease (aGvHD) in hematopoietic stem cell transplantation (HSCT). Dynamic surveillance of the microbiota reveals changes in composition and related cytokines, indicating potential avenues for prevention and treatment of aGvHD.
Review
Immunology
Rachel Limpert, Pan Pan, Li-Shu Wang, Xiao Chen
Summary: Allogeneic hematopoietic stem cell transplantation is a potential cure for hematologic malignancies, but graft-versus-host disease remains a major obstacle. Non-genetic factors, including nutrition, play a role in the development of GVHD. Understanding the impact of diet can help reduce the risk and manage GVHD.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Jaroslaw Bilinski, Marcin Jasinski, Grzegorz W. Basak
Summary: The number of allogeneic hematopoietic stem cell transplantations is increasing globally, leading to a rise in complications, particularly graft-versus-host disease (GvHD). Steroid administration is the standard treatment, but its efficacy is limited, and alternative options are still under debate. Fecal microbiota transplantation (FMT) has shown promising results in treating steroid-resistant acute GvHD by restoring the immunomodulatory role of the gut microbiota.
Letter
Medicine, General & Internal
Anna R. Schreiber, Dara L. Aisner, Jonathan A. Gutman
Summary: This article reports a case of fetal-induced graft-versus-host disease, in which the mother developed fever, pancytopenia, and rash 3 weeks after the delivery of twin sons that included transfusion.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Immunology
Tao Hong, Rui Wang, Xiaoqi Wang, Shijie Yang, Weihao Wang, Qiangguo Gao, Xi Zhang
Summary: Allogeneic hematopoietic stem cell transplantation is an effective therapy for hematological disorders, but acute graft-versus-host disease remains a major obstacle with potentially high mortality rates. Imbalance in intestinal microbiota is associated with the development and severity of aGVHD, impacting clinical outcomes following allo-HSCT. Monitoring and modifying the intestinal microecology post allo-HSCT may offer promising approaches for diagnosing, preventing, or treating aGVHD in clinical settings.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Hua Jiang, Denggang Fu, Alan Bidgoli, Sophie Paczesny
Summary: Allogeneic hematopoietic cell transplantation (allo-HCT) is crucial for treating hematological malignancies, but acute and chronic graft-versus-host disease (aGVHD and cGVHD) are major complications. Understanding the roles of T cell subsets in GVHD pathogenesis is essential for identifying new therapeutic targets and improving outcomes.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Linde Dekker, Evy Sanders, Caroline A. Lindemans, Coco de Koning, Stefan Nierkens
Summary: The recovery of naive T cells plays an important role in allo-HCT by functioning as both drivers and regulators in allogeneic reactions. Adequate reconstitution of naive T cells can improve GvHD prevention while maintaining GvL effects to lower relapse risk.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Physiology
Zhengcan Zhou, Ting Shang, Xiurong Li, Hongyan Zhu, Yu-Bo Qi, Xin Zhao, Xi Chen, Zhe-Xin Shi, Guixiang Pan, Yue-Fei Wang, Guanwei Fan, Xiumei Gao, Yan Zhu, Yuxin Feng
Summary: Combining XBJ with a reduced dose of CsA showed superior efficacy in protecting gut microbiota, attenuating aGVHD progression, and improving survival rates in a murine model. This regimen also reduced levels of proinflammatory cytokines and reversed dysbiosis at various levels in the gut microbiota of aGVHD mice. The combination treatment appeared to enhance intestinal tissue integrity and reduce intestinal permeability in aGVHD mice, potentially offering a novel strategy to manage aGVHD and improve quality of life for allo-HSCT recipients.
FRONTIERS IN PHYSIOLOGY
(2021)
Article
Medicine, General & Internal
Florent Malard, Michael Loschi, Anne Huynh, Thomas Cluzeau, Sarah Guenounou, Faezeh Legrand, Leonardo Magro, Corentin Orvain, Amandine Charbonnier, Marta Panz-Klapuch, Deborah Desmier, Jean-Baptiste Mear, Jerome Cornillon, Christine Robin, Etienne Daguindau, Karin Bilger, Maria J. G. T. Vehreschild, Patrice Chevallier, Helene Labussiere-Wallet, Clemence Mediavilla, Marie-Anne Couturier, Claude-Eric Bulabois, Vincent Camus, Sylvain Chantepie, Patrice Ceballos, Beatrice Gaugler, Ernst Holler, Joel Dore, Emmanuel Prestat, Cyrielle Gasc, Emilie Plantamura, Mohamad Mohtya
Summary: This study aimed to assess the safety and efficacy of the pooled allogeneic faecal microbiota, MaaT013, for the treatment of steroid-refractory GI-aGvHD. The results showed that MaaT013 had therapeutic responses in some patients and was safe in highly immunocompromised patients.
Review
Immunology
Shuang Fan, Wen-Xuan Huo, Yang Yang, Meng-Zhu Shen, Xiao-Dong Mo
Summary: This study reports the updated results of ruxolitinib as treatment for SR-GVHD and compares the efficacy and safety between children and adults. The findings suggest that ruxolitinib is an effective and safe treatment for SR-GVHD, and both children and adults can benefit from it.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Ting Shang, Yue Guo, Xiu-Rong Li, Zhengcan Zhou, Yubo Qi, Khalid Salahdiin, Ru Shen, Shuang He, Mei Wang, Zhe-Xin Shi, Xin Zhao, Jian Yang, Guanwei Fan, Yuefei Wang, Xiumei Gao, Yan Zhu, Yuxin Feng
Summary: Preventing acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplant (allo-HSCT) remains challenging. This study suggests that combining the main components of Xuebijing (XBJ) with Cyclosporin A (CSA) can enhance the preventive effect against acute GVHD, mainly by protecting the gut from damage and maintaining a healthy intestinal microbiota balance.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Hematology
Noa G. Holtzman, Steven Z. Pavletic
Summary: Chronic graft-versus-host disease (cGVHD) is a systemic complication of allogeneic haematopoietic stem cell transplantation that can lead to increased morbidity and mortality. Despite limited curative treatment options, recent collaborative research efforts have led to discovery of new second-line therapies. Comprehensive and sustained multidisciplinary efforts are crucial for successful management of cGVHD.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Shinri Sato, Eisuke Shimizu, Jingliang He, Mamoru Ogawa, Kazuki Asai, Hiroyuki Yazu, Robert Rusch, Mio Yamane, Fan Yang, Shinji Fukuda, Yutaka Kawakami, Kazuo Tsubota, Yoko Ogawa
Summary: In this study, it was found in a mouse model that gentamicin (GM) significantly suppressed systemic cGVHD phenotypes and ocular manifestations, and reduced inflammatory cell infiltration and fibrosis in cGVHD-targeted organs. Although GM maintained higher levels of regulatory T cells, there were fewer Th17 cells and IL-6-producing macrophages in cGVHD-targeted organs. These findings suggest that orally administered GM may have positive effects in a cGVHD mouse model.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Cell Biology
Konradin F. Muskens, Caroline A. Lindemans, Mirjam E. Belderbos
Summary: GvHD is a major complication of HCT, causing severe hematopoietic dysfunction. Immune activation during GvHD damages hematopoietic stem cells and their niche in the bone marrow, leading to reduced functionality. Complications and treatments associated with HCT exacerbate hematopoietic dysfunction.
Review
Immunology
Fathima A. Mohamed, Govindarajan Thangavelu, Stephanie Y. Rhee, Peter T. Sage, Roddy S. O'Connor, Jeffrey C. Rathmell, Bruce R. Blazar
Summary: The therapeutic efficacy of allo-HSCT is limited by the development of GVHD, with immune dysregulation leading to expansion of alloreactive cells and reduction in regulatory cells. New therapies are needed to restore the balance between effector and regulatory immune cells while preserving the beneficial graft-versus-tumor effect.
FRONTIERS IN IMMUNOLOGY
(2021)
